CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.1300
-0.1700 (-3.95%)
At close: 4:00PM EDT

4.1400 +0.01 (0.24%)
After hours: 4:58PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.3000
Open4.2500
Bid4.1100 x 1000
Ask4.1500 x 1800
Day's Range4.0400 - 4.2600
52 Week Range2.5500 - 7.6700
Volume1,996,057
Avg. Volume1,713,360
Market Cap427.154M
Beta (5Y Monthly)1.95
PE Ratio (TTM)10.15
EPS (TTM)0.4070
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-32% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders

    CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced a change in the format of its 2020 Annual Meeting of Stockholders (the "Annual Meeting") from an in-person meeting to a virtual-only meeting format. The change is being made as a result of the coronavirus outbreak (COVID-19) and in order to protect the health and safety of Catalyst's stockholders and employees. There will be no in-person meeting. As previously announced, the Annual Meeting will be held on Thursday, August 20, 2020 at 9:00 a.m. eastern time. Stockholders will be able to attend the Annual Meeting and submit questions and vote their shares during the Annual Meeting, from any location that has internet connectivity. Only stockholders of record at the close of business on June 22, 2020 ("Record Date") will be entitled to attend the virtual Annual Meeting. To register for the Annual Meeting, you should follow these instructions as applicable to the nature of your ownership of our common stock: * Registered Stockholders. If your shares are registered in your name with Continental Stock Transfer & Trust Company ("Continental"), and you wish to attend the online-only virtual Annual Meeting, go to www.cstproxy.com/catalystpharma/2020, enter the control number you received on your proxy card (printed in the box and marked with an arrow) and click on the "Click Here to Preregister for the Online Meeting" link at the top of the page. Just prior to the start of the meeting you will need to log back into the meeting site using your control number. Pre-registration is recommended but is not required to attend.   * Street Name Stockholders. Street name stockholders who wish to attend the online-only virtual Annual Meeting must obtain a legal proxy by contacting their account representative at the bank, broker, or other nominee that holds their shares and email a copy (a legible photograph is sufficient) of their legal proxy to proxy@continentalstock.com. Street name stockholders who email a valid legal proxy will be issued a meeting control number that will allow them to register to attend and participate in the online-only Annual Meeting. After contacting Continental, a street name stockholder will receive an e-mail prior to the meeting with a link and instructions for entering the virtual Annual Meeting. Street name stockholders should contact Continental at least five (5) business dates prior to the Annual Meeting date.Stockholders participating in the virtual Annual Meeting will be in a listen-only mode and will not be able to speak during the webcast. However, in order to maintain the interactive nature of the virtual meeting, virtual attendees are able to: (i) vote using the online meeting website, and (ii) submit questions or comments to Catalyst's officers during the meeting via e-mail or the virtual meeting webcast. Starting Monday, August 17, 2020 at 9:00 AM eastern time, stockholders may submit questions or comments before or during the meeting through the virtual meeting portal by typing in the "Submit a Question" box.Stockholders will also have the option to call in to the virtual Annual Meeting by telephone and listen (in listen-only mode) by calling: Within the U.S. and Canada1-888-965-8995 (toll free)   Outside the U.S. and Canada1-415-655-0243 (standard rates apply)   Passcode for telephone access:09485747  We encourage you to access the Annual Meeting 15 minutes prior to the start time. Online check-in will begin at 8:45 a.m. eastern time.On or about July 6, 2020, Catalyst filed with the SEC and mailed to its stockholders a proxy statement (the "Proxy Statement") containing information about the matters to be considered at the Annual Meeting. In connection with the matters described in this press release, Catalyst is filing with the SEC and making available to its stockholders a supplement to its Proxy Statement ("Supplement") containing additional information about the matters to be considered at the Annual Meeting. Catalyst's Proxy Statement, its Supplement, and its annual report for the year ended December 31, 2019, are available for download on Catalyst's website at https://ir.catalystpharma.com/financial-information/annual-reports and on Continental's website at https://www.cstproxy.com/catalystpharma/2020.About Catalyst PharmaceuticalsCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA.Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis.Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2019 and Catalyst's other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. CONTACT: Investor Contact Brian Korb Solebury Trout (646) 378-2923 bkorb@troutgroup.com Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 pmcenany@catalystpharma.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com

  • GlobeNewswire

    Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020

    CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release second quarter 2020 financial results after market close on Monday, August 10, 2020. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, August 11, 2020 to discuss the financial results and to provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page.A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.About Catalyst PharmaceuticalsCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA.Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis.Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. CONTACT: Investor Contact Brian Korb Solebury Trout (646) 378-2923 bkorb@troutgroup.com Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 pmcenany@catalystpharma.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com

  • GlobeNewswire

    Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA

    CORAL GABLES, Fla., July 31, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit against the FDA has filed a Report and Recommendation in which she recommends to the District Judge handling the case that she grant the FDA's and Jacobus' motions for summary judgement and deny Catalyst's motion for summary judgement. Catalyst is currently reviewing the Magistrate Judge's decision, which it believes to be incorrect as a matter of law, and intends to pursue the case further with the District Judge. The decision on whether to grant or deny Catalyst's motion for summary judgement remains with the District Judge handling the case. Patrick J. McEnany, the Company's Chairman and CEO, stated: "We are obviously very disappointed with the Magistrate Judge's recommendation, which we believe is contrary to the plain language of the Orphan Drug Act. If this recommendation is correct on the law, it means that the FDA can effectively eliminate the benefits of exclusivity under the Orphan Drug Act, which we believe will chill the incentive for drug companies like Catalyst to spend the millions of dollars necessary to develop an orphan drug."Mr. McEnany continued: "This recommendation does not alter the fact that Jacobus Pharmaceuticals is not permitted under applicable law to market its amifampridine product to adult LEMS patients in the United States, and Catalyst intends to continue to aggressively take all steps necessary to protect Firdapse®’s exclusivity under the Orphan Drug Act."About Catalyst PharmaceuticalsCatalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS). Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was approved in November 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse® is now commercially available in the United States. Prior to its approval, Firdapse® for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA.Forward-Looking StatementsThis press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether Catalyst will successfully convince the District Judge to grant Catalyst's motion for summary judgment in light of the recommendation of the Magistrate Judge, (ii) whether Catalyst can continue to successfully market its product despite the lower price charged by Jacobus for its amifampridine drug, and (iii) those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2019 and Catalyst's other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. CONTACT: Investor Contact Brian Korb Solebury Trout (646) 378-2923 bkorb@troutgroup.com Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 pmcenany@catalystpharma.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com

  • Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: Catalyst Pharmaceutical (CPRX) Q2 Earnings Expected to Decline

    Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Did Hedge Funds Make The Right Call On Catalyst Pharmaceuticals, Inc. (CPRX) ?
    Insider Monkey

    Did Hedge Funds Make The Right Call On Catalyst Pharmaceuticals, Inc. (CPRX) ?

    The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]

  • SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Catalyst Pharmaceuticals, Inc. - CPRX
    Newsfile

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Catalyst Pharmaceuticals, Inc. - CPRX

    New York, New York--(Newsfile Corp. - July 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/catalyst-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, ...

  • ACCESSWIRE

    INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Catalyst Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty Claims

    NEW YORK, NY / ACCESSWIRE / July 14, 2020 / Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Catalyst Pharmaceuticals, Inc. (NASDAQ: ...

  • 3 US Small-Cap Stocks to Consider for Market Recovery
    GuruFocus.com

    3 US Small-Cap Stocks to Consider for Market Recovery

    These companies have outperformed the S&P; 500 over the past 6 months Continue reading...

  • Do Institutions Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares?
    Simply Wall St.

    Do Institutions Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares?

    A look at the shareholders of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) can tell us which group is most powerful...

  • GlobeNewswire

    Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the promotion of Jeffrey Del Carmen to Chief Commercial Officer, effective today. Mr. Del Carmen joined Catalyst in August of 2018 as Senior Vice President of Sales and Marketing. In his new role, Mr. Del Carmen will report to the CEO of Catalyst and will serve on Catalyst's Executive Leadership Team.

  • Hedge Funds Have Never Been This Bullish On Catalyst Pharmaceuticals, Inc. (CPRX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Catalyst Pharmaceuticals, Inc. (CPRX)

    In this article you are going to find out whether hedge funds think Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

  • Thomson Reuters StreetEvents

    Edited Transcript of CPRX.OQ earnings conference call or presentation 12-May-20 12:30pm GMT

    Q1 2020 Catalyst Pharmaceuticals Inc Earnings Call

  • Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?
    Zacks

    Catalyst (CPRX) Down 0.4% Since Last Earnings Report: Can It Rebound?

    Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Catalyst Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

    CORAL GABLES, Fla., June 01, 2020 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and.

  • What Does The Future Hold For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)? These Analysts Have Been Cutting Their Estimates
    Simply Wall St.

    What Does The Future Hold For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)? These Analysts Have Been Cutting Their Estimates

    One thing we could say about the analysts on Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - they aren't optimistic...

  • Catalyst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
    Simply Wall St.

    Catalyst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

    Last week, you might have seen that Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly result to the...

  • Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates
    Zacks

    Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates

    Catalyst (CPRX) delivered earnings and revenue surprises of 11.11% and -8.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update

    Firdapse® Q1 2020 Net Revenues of $29.1 MillionFirst Quarter 2020 GAAP Net Income of $10.4 MillionCatalyst Withdraws Previous 2020 Revenue Guidance Due to COVID-19.

  • GlobeNewswire

    Catalyst Pharmaceuticals to Hold First Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 12th, 2020

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release first quarter 2020 financial results after market close on Monday, May 11, 2020. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, May 12, 2020 to discuss the financial results and to provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers.

  • Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks
    TipRanks

    Healthcare Pro Steven Boyd Is Gobbling Up These 3 Stocks

    With the market’s trajectory remaining unknown, hedge fund manager Steven Boyd believes that one industry in particular still houses exciting opportunities: the healthcare sector. Compared to the broader market, the healthcare space has held up stronger, with the names battling COVID-19 seeing some serious gains.Before founding his hedge fund, Armistice Capital, in 2012, Boyd spent a significant portion of his career focusing on investments in consumer and healthcare equities. Taking that expertise with him, Boyd built Armistice into a global, long-short, value-oriented and event-driven hedge fund that boasts an impressive healthcare stock picking record. Based on the firm’s $1.7 billion worth of assets at the end of 2019, that track record speaks for itself.Taking all of this into consideration, we wanted to find out if three stocks Boyd added to the fund recently represent compelling plays in the healthcare space. Pulling up TipRanks’ database, the platform revealed that the Buy-rated tickers are backed by Wall Street analysts and sport massive upside potential. Catalyst Pharmaceuticals (CPRX)We will start with Catalyst Pharmaceuticals, which develops therapies to improve the lives of patients with debilitating, chronic neuromuscular and neurological diseases. Thanks to its lead asset, Firdapse, the company has scored several fans.Among its fan base is Boyd. His fund disclosed that it had acquired a new position in CPRX. Buying a whopping 5,378,000 shares, Armistice became a 5.2% owner of the company.Out on the Street, CPRX has earned the support of members of the analyst community, including H.C. Wainwright’s Andrew Fein. After management reported that there had been a total of 532 cumulative Firdapse patient enrollments spanning from the January 2019 commercial launch through year-end 2019, the five-star analyst believes substantial progress has been made in Lambert-Eaton myasthenic syndrome (LEMS). Additionally, the company is continuing to focus on increasing new patient starts, maintaining new patients and combatting initial patient discontinuation.“We believe the momentum of the ongoing Firdapse commercial expansion continues to be driven by directed focus and growth of sales and marketing efforts... In light of continued commercial progress in LEMS, management reiterated full-year 2020 Firdapse net revenue guidance of $135-155 million, which we note does not include global expansion efforts such as possible New Drug Submission (NDS) approval in Canada anticipated in 2H20, which we believe can provide yet further benefit to commercial efforts,” Fein commented.As about 65% of diagnosed LEMS patients haven’t been prescribed Firdapse and there’s an estimated 1,500 undiagnosed patients, Fein thinks 2020 revenue could reach $146.8 million. Based on all of this, he reiterated a Buy rating and $9 price target. (To watch Fein’s track record, click here)Like Fein, Oppenheimer’s Leland Gershell also takes a bullish approach. “Despite a WFH policy and travel ban, patient access to Firdapse remains uninterrupted, and the company has inventory through mid-2021. Also, top-line data from an SPA-sponsored pivotal trial in muscle-specific receptor tyrosine kinase (MuSK), which we see as a key catalyst for the stock, remain on track to report this quarter,” the five-star analyst commented.Even though the proof-of-concept data readout in spinal muscular atrophy (SMA) Type 3 was delayed, the program wasn’t included in Gershell’s model, so he still sees CPRX as an “attractive buy at current levels.” To this end, he left an Outperform call and $10 price target on the stock, indicating 102% upside potential. (To watch Gershell’s track record, click here)Overall, 3 Buys assigned in the last three months versus no Holds or Sells add up to a Strong Buy Street consensus. At $10, the average price target matches Gershell’s. (See Catalyst stock analysis on TipRanks)Baudax Bio, Inc. (BXRX)Specializing in the development of products for patients in acute care settings, Baudax Bio is committed to providing clinically meaningful therapeutic options. Shares are up 25% in the last month, and some market watchers believe that there’s still plenty of room for BXRX to keep on surging.This appears to be the stance taken by Boyd. Armistice initiated a new position, pulling the trigger on 899,576 shares. Along with the purchase came a 4.99% stake in BXRX.Weighing in on the healthcare name for Janney Montgomery, analyst Esther Hong has also been singing its praises. Her bullish thesis is in part driven by the company’s plans for its IV meloxicam (Anjeso) product’s U.S. launch. The therapy, which was approved back in February for the treatment of moderate-to-severe post-op pain, will be launched in June, with the company placing a significant focus on hiring and training a sales staff in preparation for the full commercial launch.Hong tells investors that once COVID-19 restrictions are eased, she predicts a spike in elective surgeries. As a result, her call for de minimis U.S. Anjeso sales of $3.1 million for the first six months after launch remains unaltered.Hong added, “Once the recommendation against non-emergency procedures is lifted, we believe Baudax will move full speed forward with its plans to target ambulatory surgical centers (ASCs) that perform the following core target procedures: orthopedic (hip/knee, spine, other), general surgery and colorectal. This translates to approximately 550 ASC accounts that perform approximately 1 million of these procedures per year.” As BXRX has also identified 1,450 inpatient and outpatient hospitals that make up 80% of the targeted market, the deal is sealed for Hong.As a result, Hong rates BXRX shares a Buy along with a $10 price target, which implies 190% upside potential. (To watch Hong’s track record, click here)Other analysts are on the same page. Based on 100% Street support, BXRX earns a Strong Buy consensus rating. In addition, the $13.33 average price target is more aggressive than Hong’s and suggests 291% upside potential. (See Baudax stock analysis on TipRanks)Pulmatrix, Inc. (PULM)Utilizing its iSPERSE technology, Pulmatrix is developing innovative pulmonary-delivered treatments for both respiratory and non-respiratory disease. While shares have already climbed 60% higher in 2020, new strategic partnerships could signal that more growth is in store.Not wanting to miss out on an opportunity, Armistice went in on PULM. The hedge fund added a new holding, disclosing the purchase of 1,320,180 shares on April 24. The implication? Boyd’s fund is now a 4.99% owner of the company.Turning now to the analyst community, Fein (who also covers CPRX) acknowledges that its Pulmazole asset is limited by poor bioavailability, pharmacokinetic variability, drug interactions and possible GI and cardiac related side effects, but he still sees an opportunity.“As Pulmazole development continues for the treatment of allergic bronchopulmonary aspergillosis (ABPA) asthmatic patients, utilizing the company’s inhaled iSPERSE formulation of prescription anti-fungal drug, itraconazole, we continue to assert that an inhaled formulation of itraconazole could offer patients improved respiratory distribution with lower systemic exposure than the oral itraconazole alternative,” the H.C. Wainwright analyst commented.On top of this, Fein argues that the iSPERSE program in general is stable, with it supported by an agreement with Cipla for the co-development and commercialization of Pulmazole, partnerships with the Lung Cancer Initiative of Johnson & Johnson and Nocion Therapeutics for inhaled drug delivery development with broader applicability. Highlighting the Johnson & Johnson collaboration specifically, the analyst noted, “We specifically maintain that the J&J agreement option for a portfolio of narrow spectrum kinase inhibitors (NSKI) in development for lung cancer, highlights the applicability of the iSPERSE approach to potentially facilitate efficacy, tolerability, and drug delivery for systemic treatment in other diseases.”Sure, there’s a chance that COVID-19 could delay the progression of trials and impact patient enrollment, but Fein points out that currently, both Phase 2 data for Pulmazole in treating ABPA in asthma patients and Phase 1b data for PUR1800 are slated for release in the first half of 2021.Bearing this in mind, Fein stayed with the bulls. Along with a Buy recommendation, he kept his $10 price target as is, putting the potential twelve-month gain at a whopping 625%.Looking at the consensus breakdown, Fein is the only analyst that has thrown an opinion into the mix recently. As a result, the stock’s consensus rating is a Moderate Buy, with the average price target matching Fein’s. (See Pulmatrix stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Is Catalyst Pharmaceuticals a Buy?
    Motley Fool

    Is Catalyst Pharmaceuticals a Buy?

    Several catalysts could drive this biopharma higher, but there are some significant risks ahead, too.

  • GlobeNewswire

    Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities

    Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today provided an update on certain impacts of COVID-19 on its business operations. “We are committed to protecting the safety and well-being of our personnel, the entire LEMS community, healthcare providers, patients in clinical trials, and clinical trial site employees, and this will remain our priority throughout these challenging times,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals.

  • Thomson Reuters StreetEvents

    Edited Transcript of CPRX earnings conference call or presentation 17-Mar-20 12:30pm GMT

    Q4 2019 Catalyst Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE

    Catalyst Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 17, 2020 / Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 17, 2020 ...

  • GlobeNewswire

    Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

    -Firdapse® Q4 Net Revenues of $30 Million, FY 19 Net Revenues of $102 Million -GAAP Net Income of $32 Million for Fiscal Year 2019 -Catalyst Reiterates Net Revenue Guidance in.